Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 105
- Registration Number
- NCT04136535
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
- Conditions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Cttq
- Target Recruit Count
- 60
- Registration Number
- NCT04106024
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT04080154
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, China
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT04073550
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 386
- Registration Number
- NCT04073537
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04004975
- Locations
- 🇨🇳
Shandong cancer hospital, Jinan, Shandong, China
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03996408
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03991975
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijin, Beijing, China
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03983928
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03975036
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.